(PRWEB) June 03, 2014
The “In-Vitro Toxicology/ Toxicity Testing Market by Industry (Diagnostic, Pharmaceutical, Cosmetics, Chemical), Technology (Cell Culture, HTS, Omics), Applications (Systemic, Dermal, Ocular),Method (Cellular Assay, Ex vivo, In Silico) - Global Forecast to 2018”.
Browse 67 market data tables, 25 figures spread through 246 pages and in-depth TOC.
Early buyers will receive 10% customization on this report.
The global market will reach $17,227 million by 2018 growing at a double-digit CAGR during the forecast period (2013–2018).
Inquire before Buying @ http://www.marketsandmarkets.com/Enquiry_Before_Buying.asp?id=209577065
The advances in the in vitro toxicology testing have presented a wide range of new technologies that help in investigating the adverse effects of environmental agents in a more mechanistic, less expensive, and time saving manner. The cell culture technology is the largest and will be the fastest growing market in the coming five years. In vitro toxicology cellular assays are of utmost interest for the initial toxicity screening of compounds in the process of drug development within the pharmaceutical industry. The 3D models are also gaining importance in in-vitro technology as they show major phenotype differences, greater stability, and longer life. These 3D models help to replicate the effect of drugs on human body to a great extent; hence, they are used for reducing the drug attrition rate.
Request for Customization @ http://www.marketsandmarkets.com/requestCustomization.asp?id=209577065
The In depth research in the in vitro toxicology testing market has brought to light that agreements, partnerships and collaboration is the key strategy followed by major players to enhance their existing portfolio. It accounted for 28% share of the total number of strategies. Major players such as Charles River Laboratories Inc. (U.S.), Covance, Inc. (U.S.), Alere, Inc. (U.S.), Agilent Technologies (U.S.), G.E. Healthcare (U.K.) and Cyprotex (U.K.) followed this strategy between 2011 and 2014. In November 2013, GE Healthcare entered into an agreement with France-based Cellectis Group; the same time Covance, Inc. reported its strategic collaboration with NeoGenomics, Inc. in U.S. and Pathoquest in France. The agreements/partnerships deals together have widened the companies’ offerings across geographies and added to their existing portfolio of products and services. These extended range of products and services are offered together by combining considerable medical leadership to encourage innovations that improve patient outcomes. Majority of the companies are relishing the chunk of revenues generated from the developed markets but have also tapped the enormous potential of the emerging markets.
Geographic analysis reveals that Europe commanded the largest share of the global in vitro toxicity testing market in 2013. This was credited to the support provided by the European government for anti-animal testing laws. The directives set by the government has further put ban on the production and sale of all animal tested cosmetics across the continent.
Globally, the market will be driven by increasing acceptance of in vitro toxicity testing methods by regulatory authorities as alternatives to in vivo testing. This has been primarily driven by demand for toxicological information on chemicals that are both existing and newly introduced into the market. The new advances in the in vitro toxicology testing have presented a wide range of new technologies that help in investigating the adverse effects of environmental agents in a more mechanistic, less expensive, and time saving manner. Organizations such as REACH foresee that more results of in vitro and in silico methods will be included in risk assessment which will promote the use of in-vitro methods for toxicology testing. The emerging countries in Asia, such as China and India, will witness high growth on account of low cost offered by these countries as well as the economic stability observed within these countries.
The market is a highly fragmented one. The dominant players in this market are Agilent Technologies (U.S.), Alere, Inc. (U.S.), Bio-Rad (U.S.), BioReliance (Sigma Aldrich) (U.S.), Catalent Pharma Solutions (U.S.), Charles River Laboratories (U.S.), Covance (U.S.), Cyprotex (U.K.), Eurofins Scientific, Inc. (U.S.), GE Healthcare (U.K.), Life Technologies Corporation (Thermo Fisher Scientific) (U.S.), and Quest Diagnostics (U.S.).
Browse Related Reports:
Point-Of-Care Diagnostics / Testing Market by Products (Glucose Monitoring & Infectious Diseases Testing Kits, Cardiac & Tumor Markers), by End Users (Self & Professional Monitoring), Over the Counter & Prescription Based - Global Forecast to 2018
In Vitro Diagnostic (IVD) Market [Instruments, Reagents & Data Management Systems] [Technique (Immunoassay, Clinical Chemistry, Molecular Diagnostics, Hematology) & Applications (Diabetes, Infectious Diseases, Cancer & Cardiology)] Systems, End Users] – Forecast To 2017
MarketsandMarkets is a global market research and consulting company based in the U.S. We publish strategically analyzed market research reports and serve as a business intelligence partner to Fortune 500 companies across the world.
MarketsandMarkets also provides multi-client reports, company profiles, databases, and custom research services. MarketsandMarkets covers thirteen industry verticals; including advanced materials, automotive and transportation, banking and financial services, biotechnology, chemicals, consumer goods, telecommunications and IT, energy and power, food and beverages, industrial automation, healthcare IT, medical devices, pharmaceuticals, semiconductor and electronics, aerospace & defense.
We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.
North - Dominion Plaza
17304 Preston Road
Suite 800, Dallas, TX 75252
Visit MarketsandMarkets Blog @ http://mnmblog.org/market-research/healthcare/biotechnology
Connect with us on LinkedIn @ http://www.linkedin.com/company/marketsandmarkets